Get access

Treatment of severe atopic dermatitis with ustekinumab: a case series of 10 patients


  • This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bjd.15262


Atopic dermatitis (AD) is a common, chronic pruritic inflammatory condition, with an estimated prevalence of 15-30% in children, and 2-10% in adults.1 Pathogenesis of AD is complex, and remains incompletely understood. Th1, Th2 and Th17 have been reported to play a role.2 Treatment of severe AD is challenging, with currently licensed systemic agents being limited by adverse effects and suboptimal therapeutic responses.

This article is protected by copyright. All rights reserved.